The best way for medical professionals to access psilocybin for training purposes is to sign up for a clinical trial, according to federal regulator Health Canada.
But advocates and experts say that’s unethical, and a waste of resources for everyone involved.
The authority tells Mugglehead that medical professionals should no longer seek exemptions under section 56 of the Controlled Drugs and Substances Act (CDSA), which up until recently had been the only route to legally access illicit substances for training and therapy.
Share this post
